A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
A clinical and molecular Phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): A study of the Princess Margaret Phase II Consortium
Stephanie Lheureux,Anna V. Tinker,Blaise A. Clarke,Prafull Ghatage,Stephen Welch,Johanne I Weberpals,Neesha C. Dhani,Marcus O. Butler,Katia Tonkin,Qian Tan,David S.P. Tan,Kelly Brooks,Janelle Ramsahai,Lisa Wang,Nhu-An Pham,Patricia Shaw,Ming-Sound Tsao,Swati Garg,Tracy Stockley,Tracy Stockley,Tracy Stockley,Amit M. Oza +21 more
TL;DR: ENMD-2076 was well tolerated with main related grade 3 toxicities being hypertension, proteinuria, and diarrhea, and warrants further investigation as a potential predictive biomarker.
Journal ArticleDOI
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
Michael Friedlander,Kathleen N. Moore,Nicoletta Colombo,Giovanni Scambia,Byoung-Gie Kim,Ana Oaknin,Alla Lisyanskaya,Gabe S. Sonke,Charlie Gourley,Susana Banerjee,Amit M. Oza,Antonio González-Martín,Carol Aghajanian,William H. Bradley,Joyce F. Liu,Cara Mathews,Frédéric Selle,Alain Lortholary,Elizabeth S. Lowe,Robert Hettle,Emuella Flood,Elena Parkhomenko,Paul DiSilvestro +22 more
TL;DR: The phase 3 SOLO1 trial as discussed by the authors showed that maintenance olaparib provided a significant progression-free survival benefit versus placebo in patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation in response after platinum-based chemotherapy.
Journal ArticleDOI
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer
Ursula A. Matulonis,Julie Lee,Brian Lasonde,William P. Tew,Afra Yehwalashet,Daniela Matei,Kian Behbakht,Jill Grothusen,Gini F. Fleming,Nita K. Lee,Jamie Arnott,Mark R. Bray,Graham C. Fletcher,Richard Brokx,Vincent Castonguay,Helen Mackay,C. Sidor,Amit M. Oza +17 more
TL;DR: ENMD-2076 has activity in platinum-resistant ovarian cancer, and observed toxicities were similar to other PO kinase inhibitors, and further work to determine appropriate biomarkers for ENMD- 2076 should be incorporated into new clinical studies.
Journal ArticleDOI
FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)
Kathleen N. Moore,Amit M. Oza,Nicoletta Colombo,Ana Oaknin,Giovanni Scambia,Domenica Lorusso,R. Farias-Eisner,Susana Banerjee,Conleth G. Murphy,Janos L. Tanyi,H. Hirte,Jason A. Konner,P.C. Lim,M. Prasad Hayes,Bradley J. Monk,Stella K. Kim,J. Wang,Patricia Pautier,Ignace Vergote,Michael J. Birrer +19 more
TL;DR: While the study did not meet the primary endpoint, promising and consistent efficacy measures were observed in the predefined subset of high FRα PROC pts treated with MIRV, and these findings suggest a favorable benefit-risk profile for M IRV in this biomarker-defined and difficult-to-treat population.
Journal ArticleDOI
Targeting Wee1-like protein kinase to treat cancer.
Anastasios Stathis,Amit M. Oza +1 more
TL;DR: Results of preclinical studies with Wee1 inhibitors and the results of the first clinical trial recently reported, evaluating MK-1775, a small-molecule inhibitor of Wee1 are presented.